NCT02611323 2023-10-10A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)Hoffmann-La RochePhase 1/2 Completed133 enrolled 39 charts
NCT01992653 2023-03-14A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's LymphomaGenentech, Inc.Phase 1/2 Completed85 enrolled 34 charts